382 related articles for article (PubMed ID: 8093577)
21. Pathophysiology of motor fluctuations in Parkinson's disease.
Widnell K
Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in pharmacological therapy of Parkinson's disease.
Riederer P; Lange KW; Youdim MB
Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
[TBL] [Abstract][Full Text] [Related]
23. Neurochemical anatomy of movement disorders.
Young AB; Penney JB
Neurol Clin; 1984 Aug; 2(3):417-33. PubMed ID: 6152481
[TBL] [Abstract][Full Text] [Related]
24. The subthalamic nucleus: a possible target for stereotaxic surgery in Parkinson's disease.
Guridi J; Luquin MR; Herrero MT; Obeso JA
Mov Disord; 1993 Oct; 8(4):421-9. PubMed ID: 8232351
[TBL] [Abstract][Full Text] [Related]
25. Parkinson's disease. The L-dopa era.
Yahr MD
Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
[No Abstract] [Full Text] [Related]
26. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Bravi D; Davis TL; Mouradian MM; Chase TN
Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
[TBL] [Abstract][Full Text] [Related]
27. [Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP; Rüther E
Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
[No Abstract] [Full Text] [Related]
28. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
Wolfarth S
Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834
[No Abstract] [Full Text] [Related]
29. Mechanisms compensating for dopamine loss in early Parkinson disease.
Brotchie J; Fitzer-Attas C
Neurology; 2009 Feb; 72(7 Suppl):S32-8. PubMed ID: 19221312
[TBL] [Abstract][Full Text] [Related]
30. Role of neostriatal and mesostriatal or mesolimbic dopaminergic fibres in Parkinson's disease with and without dementia: prospects, concepts and facts.
Cools AR
Yakubutsu Seishin Kodo; 1990 Mar; 10(1):15-34. PubMed ID: 2220127
[No Abstract] [Full Text] [Related]
31. Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease.
Narabayashi H
Adv Neurol; 1999; 80():501-4. PubMed ID: 10410763
[No Abstract] [Full Text] [Related]
32. A review of some aspects of the pharmacology of levodopa.
Morris JG
Clin Exp Neurol; 1978; 15():24-50. PubMed ID: 386308
[TBL] [Abstract][Full Text] [Related]
33. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
Strange PG
Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
[TBL] [Abstract][Full Text] [Related]
34. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.
Mercuri NB; Calabresi P; Bernardi G
Neurology; 1989 Aug; 39(8):1106-8. PubMed ID: 2569697
[No Abstract] [Full Text] [Related]
35. Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered.
Braak H; Del Tredici K
Exp Neurol; 2008 Jul; 212(1):226-9. PubMed ID: 18501351
[TBL] [Abstract][Full Text] [Related]
36. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
Rascol OJ; Sabatini U; Chollet F; Montastruc JL; Marc-Vergnes JP; Rascol A
Adv Neurol; 1993; 60():419-21. PubMed ID: 8420165
[No Abstract] [Full Text] [Related]
37. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
Hornykiewicz O
Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
[No Abstract] [Full Text] [Related]
38. [The distribution of orientation-selective neurons in the thalamic nuclei and striopallidal complex of the human brain].
Abdullaev IaG; Medvedev SV
Neirofiziologiia; 1989; 21(5):652-60. PubMed ID: 2601764
[TBL] [Abstract][Full Text] [Related]
39. [Characteristics of the spontaneous and evoked activity of neurons of human deep brain structures during voluntary movements].
Raeva SN; Kadin AL
Fiziol Zh SSSR Im I M Sechenova; 1973 Feb; 59(2):198-205. PubMed ID: 4764377
[No Abstract] [Full Text] [Related]
40. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
